BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 1,091 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 1,091 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $27,275.00. Following the completion of the transaction, the insider now owns 58,816 shares in the company, valued at $1,470,400. This represents a 1.82 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $25.06 on Friday. The company has a market capitalization of $1.18 billion, a PE ratio of -23.64 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55. The company has a 50-day simple moving average of $26.64 and a 200 day simple moving average of $25.51.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter last year, the business posted ($0.21) EPS. On average, research analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. KeyCorp lifted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Northland Securities upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, HC Wainwright boosted their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, BioLife Solutions presently has a consensus rating of “Moderate Buy” and an average target price of $29.86.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors have recently added to or reduced their stakes in the business. State Street Corp increased its stake in shares of BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC boosted its holdings in BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after buying an additional 18,473 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in BioLife Solutions by 40.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after buying an additional 5,638 shares during the period. Barclays PLC grew its stake in BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after buying an additional 10,803 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new stake in BioLife Solutions during the 3rd quarter valued at $1,018,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.